Aligos Therapeutics Announces IND Clearance For NASH Lead, ALG-055009
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics has announced that it has received Investigational New Drug (IND) clearance for its Nonalcoholic Steatohepatitis (NASH) lead, ALG-055009. This clearance will allow the company to proceed with clinical trials.
September 21, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics has received IND clearance for its NASH lead, ALG-055009. This is a positive development for the company as it can now proceed with clinical trials.
The IND clearance is a significant regulatory milestone for Aligos Therapeutics. It allows the company to proceed with clinical trials for its NASH lead, ALG-055009. This development is likely to have a positive impact on the company's stock in the short term as it indicates progress in the company's product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100